{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:01:09Z","timestamp":1793325669075,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007231","name":"Cornell University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007273","name":"Weill Cornell Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006559","name":"University of Tsukuba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.humpath.2014.05.015","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T05:30:45Z","timestamp":1402551045000},"page":"1918-1927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6709-4000","authenticated-orcid":false,"given":"Joichi","family":"Usui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya G.","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra B.","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos D.","family":"Flombaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya V.","family":"Seshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2014.05.015_bb0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling\u2014in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr Rev"},{"key":"10.1016\/j.humpath.2014.05.015_bb0015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.humpath.2014.05.015_bb0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1053\/j.ajkd.2007.04.025","article-title":"Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension","volume":"50","author":"Izzedine","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.humpath.2014.05.015_bb0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1345\/aph.1L426","article-title":"Intricacies of bevacizumab-induced toxicities and their management","volume":"43","author":"Gressett","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.humpath.2014.05.015_bb0030","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2014.05.015_bb0035","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.semnephrol.2010.09.006","article-title":"Biology of anti-angiogenic therapy-induced thrombotic microangiopathy","volume":"30","author":"Eremina","year":"2010","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Bollee","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.humpath.2014.05.015_bb0045","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/ndt\/gfp666","article-title":"Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy","volume":"25","author":"Costero","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.humpath.2014.05.015_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Frangie","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0055","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/ndt\/gfl565","article-title":"Thrombotic microangiopathy and anti-VEGF agents","volume":"22","author":"Izzedine","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.humpath.2014.05.015_bb0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/annonc\/mdp472","article-title":"Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib","volume":"21","author":"Overkleeft","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0065","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/ncpneph0476","article-title":"Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma","volume":"3","author":"Roncone","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0070","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ki.2008.256","article-title":"Glomerular disease related to anti-VEGF therapy","volume":"74","author":"Stokes","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.humpath.2014.05.015_bb0075","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s12094-010-0550-4","article-title":"Aflibercept (VEGF Trap): one more double-edged sword of anti-VEGF therapy for cancer?","volume":"12","author":"Jin","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0080","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.humpath.2014.05.015_bb0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11591240-000000000-00000","article-title":"Axitinib for the management of metastatic renal cell carcinoma","volume":"11","author":"Escudier","year":"2011","journal-title":"Drugs R D"},{"key":"10.1016\/j.humpath.2014.05.015_bb0090","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.humpath.2014.05.015_bb0095","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.2337\/db08-0647","article-title":"Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice","volume":"57","author":"Ku","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.humpath.2014.05.015_bb0100","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2010030295","article-title":"Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling","volume":"21","author":"Sison","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0105","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2010.64","article-title":"Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease","volume":"77","author":"Veron","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.humpath.2014.05.015_bb0110","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1172\/JCI17423","article-title":"Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases","volume":"111","author":"Eremina","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.humpath.2014.05.015_bb0115","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1681\/ASN.2005080810","article-title":"Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival","volume":"17","author":"Eremina","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ncpneph0880","article-title":"How should women with pre-eclampsia be followed up? New insights from mechanistic studies","volume":"4","author":"Hertig","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0125","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1053\/j.ajkd.2006.11.024","article-title":"Nephrotic syndrome after bevacizumab: case report and literature review","volume":"49","author":"George","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.humpath.2014.05.015_bb0130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/ndt\/gfn625","article-title":"Biopsy-proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?","volume":"24","author":"Winn","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.humpath.2014.05.015_bb0135","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/ndt\/gfp140","article-title":"Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma","volume":"24","author":"Rolleman","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.humpath.2014.05.015_bb0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000241551","article-title":"Nephrotic syndrome and acute renal failure apparently induced by sunitinib","volume":"2","author":"Chen","year":"2009","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0145","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/jnci\/djm311","article-title":"A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib","volume":"100","author":"Patel","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2014.05.015_bb0150","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0002-9343(91)80022-E","article-title":"Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature","volume":"90","author":"McDonald","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.humpath.2014.05.015_bb0155","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.humpath.2014.05.015_bb0160","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.humpath.2014.05.015_bb0165","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-0968.2003.00127.x","article-title":"Drug-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome: a concise review","volume":"8","author":"Dlott","year":"2004","journal-title":"Ther Apher Dial"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817714002354?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817714002354?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:34:23Z","timestamp":1758645263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817714002354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0046817714002354"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2014.05.015","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2014.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}